CORDIS
EU research results

CORDIS

English EN
High Performance Soft-tissue Navigation

High Performance Soft-tissue Navigation

Objective

Primary liver cancer, which consists predominantly of hepatocellular carcinoma (HCC), is the fifth most common cancer worldwide and the third most common cause of cancer mortality. A successful surgical resection of HCC requires complete removal of the tumour while sparing as much healthy tissue as possible. Due to technical and clinical difficulties relatively low percentage of patients are eligible for resection. There is an urgent need to increase the patient eligibility and improve the survival prognosis after liver interventions. HiPerNav will train early stage researchers (biomedical engineers and medical doctors) to become international leading in key areas of expertise through a novel coordinated plan of individual research projects addressing specific bottlenecks in soft tissue navigation for improved treatment of liver cancer. The multi-disciplinary dialogue and work between clinicians and biomedical engineers is crucial to address these bottlenecks. By providing researchers with knowledge and training within specific topics from minimally invasive treatment, biomedical engineering, research methodologies, innovation and entrepreneurship, the link between academic research and industry will be strengthened. This allows for easy transfer of promising results from the research projects to commercially exploitable solutions. The global image guided surgery devices market is promising; it was valued at USD 2.76 billion in 2013 and is projected to expand 6.4% from 2014 to 2022 to reach USD 4.80 billion in 2022. The market for soft-tissue navigation is still in its infancy, mainly due to challenges in achieved accuracy for targeting deformable and moving organs. By providing multi-disciplinary training, the researchers in this consortium of international leading research institutions, universities and industry will initiate true translational research from academic theoretical ideas to the clinical testing of prototype, developed solutions and tools.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

OSLO UNIVERSITETSSYKEHUS HF

Address

Kirkeveien 166 Tarnbygget
0450 Oslo

Norway

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 755 448,55

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSIDAD DE CORDOBA

Spain

EU Contribution

€ 495 745,92

NORGES TEKNISK-NATURVITENSKAPELIGE UNIVERSITET NTNU

Norway

EU Contribution

€ 572 550,48

UNIVERSITE PARIS 13

France

EU Contribution

€ 262 875,60

CASCINATION AG

Switzerland

EU Contribution

€ 265 226,76

UNIVERSITAET BERN

Switzerland

EU Contribution

€ 530 453,52

INSTITUT NATIONAL DE RECHERCHE ENINFORMATIQUE ET AUTOMATIQUE

France

EU Contribution

€ 525 751,20

STIFTELSEN SINTEF

Norway

EU Contribution

€ 111 329,26

TECHNISCHE UNIVERSITEIT DELFT

Netherlands

EU Contribution

€ 347 592,77

SINTEF AS

Norway

EU Contribution

€ 174 945,98

Partners (4)

Sort alphabetically

Expand all

SIEMENS HEALTHCARE GMBH

NVIDIA Corporation

Innovasjon Norge

YES!Delft

Project information

Grant agreement ID: 722068

Status

Ongoing project

  • Start date

    1 November 2016

  • End date

    31 October 2020

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 4 041 920,04

  • EU contribution

    € 4 041 920,04

Coordinated by:

OSLO UNIVERSITETSSYKEHUS HF

Norway